Last reviewed · How we verify
Antibacterial therapies
Antibacterial therapies work by inhibiting bacterial growth and survival through various mechanisms such as cell wall disruption, protein synthesis inhibition, or DNA damage.
Antibacterial therapies work by inhibiting bacterial growth and survival through various mechanisms such as cell wall disruption, protein synthesis inhibition, or DNA damage. Used for Bacterial infections (broad spectrum, specific indications depend on individual agents used).
At a glance
| Generic name | Antibacterial therapies |
|---|---|
| Sponsor | Mansoura University Hospital |
| Drug class | Antibacterial agent (broad class) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Antibacterial therapies encompass a broad class of antimicrobial agents that target essential bacterial processes. These may include beta-lactams that disrupt peptidoglycan synthesis, aminoglycosides that inhibit ribosomal protein synthesis, fluoroquinolones that inhibit DNA gyrase, or other mechanisms. The specific mechanism depends on the individual antibiotic agent used.
Approved indications
- Bacterial infections (broad spectrum, specific indications depend on individual agents used)
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, vomiting)
- Allergic reactions
- Photosensitivity (fluoroquinolones)
- Tendinopathy (fluoroquinolones)
- Ototoxicity (aminoglycosides)
Key clinical trials
- Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection (PHASE1, PHASE2)
- Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children (NA)
- Comparison of Oral Antibiotics For Bone Infections of the Leg and Foot (PHASE4)
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
- Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
- A Study of Doxycycline to Treat Chlamydial Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antibacterial therapies CI brief — competitive landscape report
- Antibacterial therapies updates RSS · CI watch RSS
- Mansoura University Hospital portfolio CI